Fundamental Analysis

Ratin DSIJ / 02 Jul 2026 / Categories: Flash News Investment App, Recommendations

1 stock recommendation each based on Fundamental and Technical analysis along with timely review to provide you with handsome profits.

1 stock recommendation each based on Fundamental and Technical analysis along with timely review to provide you with handsome profits.[EasyDNNnews:PaidContentStart]

GLAND PHARMA LTD
Ticker: 543245
BUY: ₹2468.90
Target: ₹2,765.00

Gland Pharma is a sterile injectables-focused pharmaceutical company with a strong presence in regulated markets, especially the US. Its base business is supported by complex injectables, ready-to-use infusion bags, GLP-1/insulin products, and CDMO opportunities, while Cenexi adds European manufacturing strength. In FY26, it launched 31 US products and had 388 cumulative ANDA filings, with 337 approved and 51 pending. Financially, Gland Pharma delivered a strong Q4FY26 and FY26 performance. In Q4FY26, consolidated revenue from operations rose 22 per cent YoY to Rs 1,742.8 crore, while adjusted EBITDA grew 51 per cent YoY to Rs 524.4 crore. Adjusted PAT nearly doubled, rising 97 per cent YoY to Rs 366.7 crore. For FY26, revenue increased 14 per cent YoY to Rs 6,430.7 crore, adjusted EBITDA rose 33 per cent YoY to Rs 1,682.6 crore, and adjusted PAT grew 50 per cent YoY to Rs 1,045.5 crore. Given the company’s growth potential, we recommend BUY.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

To read the entire article, you must be a FNI Weekly Subscriber.

[EasyDNNnews:UnPaidContentEnd]